TY - JOUR
T1 - Clinicopathological significance of JAK2, STAT3, and STAT4 expression in patients with gastric solid-type poorly differentiated adenocarcinoma
T2 - a retrospective study
AU - Umekita, Shinya
AU - Kiyozawa, Daisuke
AU - Honma, Hitoshi
AU - Kohashi, Kenichi
AU - Taniguchi, Yoshiaki
AU - Kawatoko, Shinichiro
AU - Sasaki, Taisuke
AU - Ihara, Eikichi
AU - Oki, Eiji
AU - Nakamura, Masafumi
AU - Ogawa, Yoshihiro
AU - Oda, Yoshinao
N1 - Publisher Copyright:
© The Author(s) under exclusive licence to The International Gastric Cancer Association and The Japanese Gastric Cancer Association 2025.
PY - 2025/5
Y1 - 2025/5
N2 - Background: The role of janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling remains unclear in gastric solid-type poorly differentiated adenocarcinoma. The present study investigates the clinicopathological significance of JAK2, STAT3, and STAT4 expression in solid-type poorly differentiated adenocarcinoma. Methods: We retrospectively enrolled 102 participants with primary solid-type poorly differentiated adenocarcinoma. We categorized participants according to deficient or proficient mismatch repair status (46 and 56 participants, respectively). Expression of phosphorylated JAK2 (pJAK2), phosphorylated STAT3 (pSTAT3), and STAT4 were analyzed via immunohistochemistry. We analyzed differences in protein expression in relation to mismatch repair status, and associations of high/low protein expression with clinicopathological characteristics and prognoses. Results: Deficient mismatch repair was found to be associated with high pJAK2 (p = 0.038) and STAT4 (p = 0.023) expression in contrast to proficient mismatch repair. Log-rank analysis revealed high pSTAT3 and low STAT4 expression to be significantly correlated with reduced overall survival (p = 0.001). Multivariate analysis revealed high pSTAT3 and low STAT4 expression to be independent indicators of unfavorable prognosis (hazard ratio = 2.751, p = 0.030), as was proficient mismatch repair status (hazard ratio = 3.819, p = 0.012). Conclusions: High expression of pJAK2 and STAT4 is more frequent in deficient compared with proficient mismatch repair in solid-type poorly differentiated adenocarcinoma. High pSTAT3 and low STAT4 expression could be a useful prognostic indicator in solid-type poorly differentiated adenocarcinoma.
AB - Background: The role of janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling remains unclear in gastric solid-type poorly differentiated adenocarcinoma. The present study investigates the clinicopathological significance of JAK2, STAT3, and STAT4 expression in solid-type poorly differentiated adenocarcinoma. Methods: We retrospectively enrolled 102 participants with primary solid-type poorly differentiated adenocarcinoma. We categorized participants according to deficient or proficient mismatch repair status (46 and 56 participants, respectively). Expression of phosphorylated JAK2 (pJAK2), phosphorylated STAT3 (pSTAT3), and STAT4 were analyzed via immunohistochemistry. We analyzed differences in protein expression in relation to mismatch repair status, and associations of high/low protein expression with clinicopathological characteristics and prognoses. Results: Deficient mismatch repair was found to be associated with high pJAK2 (p = 0.038) and STAT4 (p = 0.023) expression in contrast to proficient mismatch repair. Log-rank analysis revealed high pSTAT3 and low STAT4 expression to be significantly correlated with reduced overall survival (p = 0.001). Multivariate analysis revealed high pSTAT3 and low STAT4 expression to be independent indicators of unfavorable prognosis (hazard ratio = 2.751, p = 0.030), as was proficient mismatch repair status (hazard ratio = 3.819, p = 0.012). Conclusions: High expression of pJAK2 and STAT4 is more frequent in deficient compared with proficient mismatch repair in solid-type poorly differentiated adenocarcinoma. High pSTAT3 and low STAT4 expression could be a useful prognostic indicator in solid-type poorly differentiated adenocarcinoma.
KW - JAK2
KW - MSI
KW - PDA
KW - STAT3
KW - STAT4
UR - http://www.scopus.com/inward/record.url?scp=85218190378&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85218190378&partnerID=8YFLogxK
U2 - 10.1007/s10120-025-01589-8
DO - 10.1007/s10120-025-01589-8
M3 - Article
C2 - 39961990
AN - SCOPUS:85218190378
SN - 1436-3291
VL - 28
SP - 455
EP - 464
JO - Gastric Cancer
JF - Gastric Cancer
IS - 3
ER -